Tender leakage in pharma logistics — measuring the silent 30% cost

1. What is tender leakage

Tender leakage is the gap between the freight cost a pharma logistics team expects (based on the awarded tender rates) and what they actually pay (after spot freight, accessorial charges and lane-mix shifts).

It comes from several sources:

• Spot freight — when demand exceeds the awarded carrier's contracted capacity, the overflow goes to spot at substantially higher rates (typically 1.4–2.5× contract).
• Out-of-contract lanes — production-plan shifts open lanes that weren't in the tender; these almost always go to spot.
• Carrier non-acceptance — awarded carriers occasionally refuse tendered loads (capacity, mode mismatch); the load reverts to spot.
• Accessorial creep — fuel surcharges, temperature-control surcharges, weekend pickup surcharges that weren't priced into the contract.

Each individual leak is small. The aggregate, in our observation across mid-size pharma logistics operations, runs at 0.8–1.6% of total freight spend annually — on top of an already-tendered baseline. For €25M annual spend, that's €200–400K of avoidable cost.

2. Why it's invisible to most teams

Three structural reasons:

1. Invoice arrival lag. Spot freight invoices arrive 30–60 days after the move. By the time the variance is visible in the GL, the planner who could have prevented it has moved on to next quarter's plan.
2. Variance hidden in carrier mix. Most logistics dashboards show total freight cost vs budget. Leakage is hidden because the budget itself incorporates an expected spot ratio — actuals "look normal" even when they're 2pp above the contracted ratio.
3. No SKU × lane × month resolution. Aggregate metrics smooth over the tail. The lanes that drive 80% of the leakage are usually 5–10 specific SKU-lane pairs with high demand volatility; you can't see them unless you slice the data at the right resolution.

3. Methodology — measuring leakage across SKU × lane × month

The measurement methodology requires three data sources:

• Active tender contract — awarded carriers per lane, contracted rates, expected volumes.
• Actual shipment data — every shipment with SKU, lane (origin–destination), date, volume, carrier, rate paid (contract or spot).
• Production plan history — the rolling production plan as it changed week-over-week (most TMS / SAP exports lose the version history; we typically need to reconstruct from MRP exports).

The metric:

Negative values are good (under spot ratio). Positive values are leakage. The interesting question is the distribution of per-lane leakage across the portfolio — typically a few lanes drive most of the dollar exposure.

4. Scoring lanes by tail-risk exposure

Not all leakage is equally actionable. A lane with 4% leakage on €50K annual spend (€2K leak) is interesting for measurement but not worth an intervention round. A lane with 1.2% leakage on €4M annual spend (€48K leak) is.

The scoring approach we recommend:

1. Estimate the per-lane spend distribution for the next quarter (Monte Carlo, using historical volatility).
2. Apply per-lane historical leakage rate with its uncertainty band.
3. Compute expected leakage dollar value at the 80^th-percentile worst case.
4. Rank lanes by 80^th-percentile leakage — these are the intervention targets.

For a typical mid-size pharma operation, we see ~10% of lanes account for ~70% of the leakage exposure. Mini-tendering these specific lanes is dramatically more efficient than re-running the full annual tender early.

5. Intervention — mini-tender before invoices reconcile

The structural inefficiency of pharma freight tendering is that the annual cadence is too coarse for production-plan reality. Mini-tenders for the high-leakage lanes, run in 2–3 week cycles, capture the savings without the overhead of a full re-tender.

The Synlogica Terminus Logistics workflow for this:

1. Production-plan ingestion identifies lanes with capacity gap forecast (Monte Carlo distribution of demand vs contracted capacity per lane).
2. Lane scoring surfaces the 3–5 highest-tail-risk lanes for the next 4–8 weeks.
3. Mini-tender package generated — RFP-quality document with required mode, volume, temperature class, pickup window, target award date.
4. Decision package logs the intervention rationale, lanes selected, savings forecast, expected award date.

Critically: the decision package is generated before the spot invoices arrive, so the savings are realized rather than reconciled after-the-fact.

6. Case structure — mid-size pharma, €25M freight spend

The capture rate is bounded by carrier acceptance — some lanes have structural capacity constraints that no tender will fully solve. The remaining ~15–30% of identified leakage is structural and must be priced into the next annual tender as expected cost rather than chased reactively.

7. Takeaways

1. Tender leakage is the gap between expected freight cost (tender rates × expected volumes) and actual cost; in pharma it typically runs 0.8–1.6% of total freight spend on top of an already-tendered baseline.
2. It's structurally invisible because (a) invoice arrival lag, (b) carrier-mix dashboards hide it, (c) aggregate metrics smooth over the tail.
3. The measurement requires SKU × lane × month resolution and three data sources — contract, actuals, production-plan history.
4. ~10% of lanes typically account for ~70% of dollar leakage exposure. These are mini-tender targets.
5. Intervention is mini-tendering the high-tail-risk lanes in 2–3 week cycles, generated before spot invoices reconcile.
6. Realistic capture after intervention is ~70–85% of identified leakage — the remainder is structural and prices into the next annual tender.